As eye care specialists, you frequently co-manage patients with other health care providers such as primary care physicians, rheumatologists, and neurologists. This often makes you the first line of detection when certain medications prescribed by those physicians start negatively impacting the patient’s retina. In some cases, retinal dysfunction may occur without structural abnormalities, requiring a robust functional testing method to detect retinal toxicity early. Diopsys® mfERG (multifocal electroretinography) vision tests provide you with the objective, functional information you need to help recognize the first signs of drug-induced retinopathy, and work with the other providers to make the best clinical decisions for each patient.

• Objectively monitor function loss and recovery with objective, quantitative metrics
• Co-manage patients more efficiently for more timely changes to treatment
• Understandable and simple reporting

Multifocal Electroretinography (mfERG) Vision Testing

Multifocal ERG has been recognized as an effective test in helping doctors to diagnose and manage diseases affecting the retina, most notably retinal toxicities. This visual electrophysiology technique is a test of localized retinal function through quasi-simultaneous stimulation of different areas of the retina. The American Academy of Ophthalmology (AAO) recommends the use of multifocal electroretinography for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy screening.